Discovery of novel triple helical DNA intercalators by an integrated virtual and actual screening platform by Holt, A et al.
1280–1287 Nucleic Acids Research, 2009, Vol. 37, No. 4 Published online 9 January 2009
doi:10.1093/nar/gkn1043
Discovery of novel triple helical DNA intercalators
by an integrated virtual and actual screening
platform
Patrick A. Holt1,3, Patricia Ragazzon1, Lucjan Strekowski4,
Jonathan B. Chaires1,2,3 and John O. Trent1,2,3,*
1James Graham Brown Cancer Center, 2Department of Medicine, 3Department of Biochemistry and Molecular
Biology, University of Louisville, 529S. Jackson Street, Louisville, KY 40202 and 4Department of Chemistry,
Georgia State University, Atlanta, GA 30302, USA
Received November 21, 2008; Revised December 12, 2008; Accepted December 13, 2008
ABSTRACT
Virtual Screening is an increasingly attractive way
to discover new small molecules with potential
medicinal value. We introduce a novel strategy that
integrates use of the molecular docking software
Surflex with experimental validation by the method
of competition dialysis. This integrated approach
was used to identify ligands that selectively bind to
the triplex DNA poly(dA)-[poly(dT)]2. A library con-
taining ~2 million ligands was virtually screened to
identify compounds with chemical and structural
similarity to a known triplex intercalator, the
napthylquinoline MHQ-12. Further molecular dock-
ing studies using compounds with high structural
similarity resulted in two compounds that were
then demonstrated by competition dialysis to have
a superior affinity and selectivity for the triplex
nucleic acid than MHQ-12. One of the compounds
has a different chemical backbone than MHQ-12,
which demonstrates the ability of this strategy to
‘scaffold hop’ and to identify small molecules with
novel binding properties. Biophysical characteriza-
tion of these compounds by circular dichroism and
thermal denaturation studies confirmed their bind-
ing mode and selectivity. These studies provide a
proof-of-principle for our integrated screening strat-
egy, and suggest that this platform may be extended
to discover new compounds that target therapeuti-
cally relevant nucleic acid morphologies.
INTRODUCTION
Nucleic acid sequences that form triple helices have
become a source of increasing interest as a way to interfere
with DNA transcription and modulate gene expression
(13). Several approaches attempt to use triplex nucleic
acids to interfere with the transcription of genes, through
either inducing the formation of triplex or stabilizing
existing triplex nucleic acids. The former approach is the
so-called ‘anti-gene’ approach and involves the adminis-
tration of triplex forming oligonucleotides (TFOs), which
are short sequences of nucleic acids that can bind to the
major groove of duplex nucleic acids and promote the
formation of triplex structures (4,5). TFOs have already
been successful in reducing transcription of the c-myc
oncogene that is located in the promoter site of genes
(4,6). However, there are currently signiﬁcant challenges
associated with the use of TFOs and triplex structures in
general. First, TFOs have signiﬁcantly lower activity in
cell-based systems, compared to in vitro systems (7). This
has been ascribed to many factors including improper cel-
lular localization or degradation of the oligonucleotide
(7,8). A second limitation is the inherent low stability of
many triplex structures (9,10). The latter limitation is the
focus of this work where we demonstrate the use of a
novel virtual and actual screening platform for identifying
several compounds that can selectively bind to and stabi-
lize a triplex nucleic acid structure. These newly identiﬁed
small molecules could be used to target triplex structures
in several ways. First, the small molecule could stabilize
pre-existing triplex structures in vivo. The small molecules
could be used in an adjuvant setting with TFOs to increase
stability, or alternatively the small molecules can be linked
to TFOs to enhance the stability of newly formed triplex
structures (8). Either of these approaches could be used to
control gene expression. These capabilities make these
small molecules potentially clinically relevant for treating
cancer and other diseases that are closely linked with
abnormal gene expression.
Several small molecules are known to intercalate into
and stabilize triplex nucleic acids including coralyne, ben-
zo[e]pyridoindoles (BePI), benzo[g]pyridoindoles (BgPI),
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dibenzophenanthrolines, and anthraquinones (1014).
One of the most selective and extensively studied classes
are the napthylquinolines, which have been shown to
intercalate into the TAT DNA triplex, poly(dA)-
[poly(dT)]2 (1517). Chaires et al. performed an extensive
study (18) that characterized the selectivity and aﬃnity
of 14 napthylquinoline derivatives. The ligand MHQ-12
emerged from that study as the compound with the high-
est aﬃnity and greatest selectivity for the poly(dA)-
[poly(dT)]2 triplex. While this approach for the discovery
of triplex-selective ligands was successful, it is a laborious
and time-consuming process. We propose a novel alterna-
tive approach for ﬁnding ligands that target a particular
structure in which virtual screening is used to identify
promising ligand candidates followed by validation using
competition dialysis. We demonstrate here that this
approach can identify small molecules that intercalate
into poly(dA)-[poly(dT)]2 with higher selectivity and aﬃn-
ity than MHQ-12. A signiﬁcant result of this approach is
that a small molecule with a substantially diﬀerent molec-
ular scaﬀold was identiﬁed that has superior aﬃnity
and selectivity for triplex DNA compared to MHQ-12.
This strategy thus provides a new platform for identifying
promising small molecule drugs against nucleic acid
targets.
Virtual screening using molecular similarity and dock-
ing methods is becoming an increasingly important and
economical approach to identify small molecule drug can-
didates (19). While there are numerous studies using such
screening methods for targeting proteins, far fewer virtual
screening eﬀorts have been performed targeting nucleic
acids. The few studies that have been performed targeting
nucleic acids have produced promising results. They have
shown that screening methods can accurately reproduce
crystallographic structures of ligand–nucleic acid com-
plexes using a variety of docking programs including
DOCK (20), Autodock (21) and Surﬂex (22). Our virtual
screening approach uses both ligand and structure-based
discovery principles to select ligands from a commercially
available library that bind to poly(dA)-[poly(dT)]2 with
higher aﬃnity and selectivity than MHQ-12. Initial virtual
screening is performed with Surﬂex-Sim, which is a ligand
similarity-based software program that has superior per-
formance compared to most traditional 2D similarity
methods (23). This program is an eﬀective tool to rapidly
pre-screen large virtual compound libraries to enrich for
structurally similar ligands (23). Surﬂex-Sim maximizes
3D morphological similarity and alignment of a test
ligand to the control ligand, which in this work was
MHQ-12 (23–25). The quantitative metric that is used
for evaluating Surﬂex-Sim results is the Surﬂex-Sim
score, which embodies an all atom comparison and align-
ment of the test ligand with the control ligand. The top-
ranked Surﬂex-Sim results were used for structure-based
docking studies to dock the ligand to the intercalation site
and the three grooves (major–major, major–minor and
minor) (18) of the triplex structure using the docking pro-
gram Surﬂex-Dock. Surﬂex-Dock performs docking of
test ligands to a ‘protomol’ or idealized representation
of the binding site on the nucleic acid target. The ligands
are docked to the target and the poses are ranked by a
Surﬂex Raw Score (SRS) that consists of an aﬃnity score
of the ligand for the target (25). This sequential combina-
tion of Surﬂex-Sim followed by Surﬂex-Dock produced
several ligands that had hypothesized higher binding
aﬃnity and selectivity for the triplex intercalation site,
compared to MHQ-12.
A critically important step after virtual screening is
validation by experimental testing of the top candidates.
To accomplish this, competition dialysis was employed
because of its extensive use to determine the selectivity
and aﬃnity of a small molecule for single-stranded,
duplex, triplex and quadruplex nucleic acid targets
(13,2636). The advantage of competition dialysis is
that it is not limited to the target sequence, or a simple
comparison with another form of DNA, but with as many
nucleic acid forms as are included in the assay.
Competition dialysis involves dialyzing solutions of an
array of nucleic acid sequences and structures against a
common solution containing a test ligand (26). The solu-
tion is allowed to reach equilibrium, and the amount of
ligand that is bound to each nucleic acid is measured using
either ﬂuorescence or absorbance (26). Comparison of
the total and relative amounts of ligand bound to each
nucleic acid assesses the aﬃnity and selectivity, respec-
tively, of the ligand for any included nucleic acid.
Competition dialysis testing is used here to validate the
aﬃnity and selectivity of the top virtual screening hits.
Circular dichroism and thermal denaturation were used
for further characterization of the triplex binding of the
top virtual screening candidate hits.
By using this integrated approach we have identiﬁed
small molecules that have higher selectivity and aﬃnity
for triplex poly(dA)-[poly(dT)]2 than the original mole-
cule, MHQ-12, and which are among the most selective
and tightest triplex binding molecules reported to date.
MATERIALS AND METHODS
Virtual library construction
The triplex-selective ligand MHQ-12 was constructed
and hydrogen atoms were added using Macromodel
(Schrodinger, Inc.). The ligand was energetically mini-
mized using a sequential combination of 2000 iterations
of a Steepest Descent algorithm followed by 2000 itera-
tions of a Polak-Ribier Conjugate Gradient algorithm.
AMBER ligand atom types were assigned using Sybyl
(Tripos, Inc.). The program Antechamber in the software
suite Amber (UCSF) was used to calculate AM1-BCC
charges for the ligand and to convert to a MOL2 ﬁle
format. A virtual set of 1.962 million ZINC compounds
in MOL2 format were obtained from the ZINC 2007 ‘all-
purchasable’ subset of ligands from the University of
California San Francisco (37). The ﬁrst 1.962 million
ligands were downloaded out of a total of 2.7 million
ligands from the 2007 ZINC ‘all-purchasable’ database.
The ‘Reference’ subset of the ‘all-purchasable’ library
was used directly as downloaded from the ZINC website,
and was not ﬁltered to select for ligands with any particular
chemical property. The ligand 3D coordinates were gener-
ated by using detailed methods previously described (37).
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Other ligand preparation procedures performed were pro-
tonation of the ligand based on a ‘Reference’ pH 7 condi-
tion and assignment of partial atomic charges from
AMSOL semi-empirical quantum calculations (37). The
triplex nucleic acid structure poly(dA)-[poly(dT)]2 with
an intercalation site was constructed using B-type parallel
triplex (38) with X-ray structural intercalation site back-
bone fragments [Protein Data Bank entry 1p20.ent] and
minimized holding the heavy atoms ﬁxed.
Surflex methods
The program Surﬂex (UCSF) containing both the Surﬂex-
Sim molecular similarity and the Surﬂex-Dock molecular
docking programs was run on 30 AMD Opteron 246 pro-
cessors (2.0GHz) running the Linux Red Hat operating
system for all virtual screening experiments. Surﬂex-Sim
experiments were performed using the ‘align_list’ function
to compare the MHQ-12 triplex selective ligand against
1.962 million compounds in the ZINC library. The top
350 ligands, ranked according to the highest Surﬂex-Sim
score, were selected as candidates for Surﬂex-Dock studies
and were extracted as individual MOL2 ﬁles from the
library ﬁles using inhouse PERL scripts. The Surﬂex-
Dock docking algorithm and scoring functions have
been described in detail previously (39,40). Brieﬂy,
Surﬂex-Dock operates by a surface shape-based method,
aligning each test ligand to a ‘protomol.’ The protomol
consists of a series of molecular fragments that character-
ize the surface properties of the target active site including
steric eﬀects, hydrogen bond acceptor groups and hydro-
gen bond donor groups (39,40). After alignment of the
ligands to the protomol, each pose is scored based on
hydrophobic and polar contacts between atoms. The scor-
ing function also includes a term for solvation although
this contribution has typically been diﬃcult to incorporate
accurately in many molecular docking programs (41).
Most importantly for these purposes, Surﬂex-Dock was
previously used successfully to reproduce the crystal struc-
tures of several mono and dicationic small molecules
bound to either the minor groove of nucleic acids or by
intercalation between base pairs (22). This suggests that
Surﬂex-Dock may have particular utility for ﬁnding new
small molecules that target nucleic acid structures and
thus is the basis for its use here. Finally, while many
other programs are generally available for molecular
docking, most have been used almost exclusively for pro-
tein–ligand docking, and have not been validated for
nucleic acid–ligand docking. The previous published use
of Surﬂex-Dock for successfully modeling binding of
ligands to nucleic acids thus makes this program a rational
selection for use in these studies (22). For the Surﬂex-
Dock experiments, four protomols were generated to
cover the major–major groove, major–minor groove,
minor groove and intercalation sites of the triplex nucleic
acid, using the same methods we previously described (22).
The ‘proto_bloat’ function was set to accommodate all
reasonable interactions of the protomols with the triplex
target sites. Docking of the ligands to the target was per-
formed using a whole molecule approach, as described
previously (22,25,39). The Surﬂex-Dock experiments
involved docking each of the ligands to all four protomols
individually, in separate experiments. Surﬂex-Dock was
operated with parameters ‘Multistart 5’ and ‘Random 5’
which we have previously shown returned accurate top-
ranked docked poses for a set of small molecules to their
respective nucleic acid targets (22). The Surﬂex-Dock
poses were ranked according to the highest Surﬂex Raw
Score. Surﬂex-Sim and Surﬂex-Dock poses were visualized
using AutoDockTools (The Scripps Research Institute).
The properties of compounds 1 and 2 used in the QSAR
analysis were generated with QikProp (Schrodinger, Inc.).
Compounds for biophysical testing
The highest ranked candidates identiﬁed by virtual screen-
ing were the ligands with ZINC identiﬁcation numbers
632255 and 4623551, which will be referred to hereafter
as compound 1 and compound 2, respectively. Compound
1 (42), is 4-(4-methylpiperazino-2-(2-naphthyl)quinoline
and was obtained from Sigma-Aldrich (Milwaukee, WI,
USA). Compound 2 is 1-phenyl-4-pyrrolidino-2,3-
-dihydro-1/H/-pyrrolo[2,3-/b/]quinoline and was obtained
from Chemical Block (N.D. Zelinsky Institute of Organic
Chemistry, Moscow, Russia). As positive controls, the
known triplex selective ligands MHQ-15 and OZ-85H
were synthesized as previously described (18).
Competition dialysis method
Competition dialysis experiments were done as previously
described (18,27,28,43). The array of oligonucleotides
used is given in Supplementary Table S1. The methods
used to construct the oligonucleotides are elaborated in
detail by Ren and Chaires (26). Brieﬂy, natural DNA
including calf thymus, Micrococcus lysodeikticus and
Clostridium perfringens were obtained from Sigma
(St Louis, MO, USA) and sonicated, phenol extracted
and puriﬁed using methods previously described (26,44).
The remaining 30-nt long oligonucleotides including
poly(dA), poly(dT), poly (dAdT), poly (dAdT)-(dAdT)
and poly (dGdC)-(dGdC) were synthesized and obtained
from Pharmacia Biotech (Piscataway, NJ, USA).
Poly(rA), poly(rU) and quadruplex sequences were
obtained from Integrated DNA Technologies (Coralville,
IA, USA). The Z-DNA structure was produced by bromi-
nation of poly (dGdC)-(dGdC), as previously described
(45). Remaining duplex nucleic acids such as poly(rArU)
were produced by mixing poly(rA) and poly(rU) in a 1:1
equimolar ratio, heating at 908C for 2min and subse-
quently cooling to room temperature. Similarly, triplex
nucleic acids were made by mixing poly (dAdT) with
poly(dT) in a 1:1 equimolar ratio, heating at 908C for
2min and subsequently cooling to room temperature.
Quadruplex nucleic acid solutions were heated at 908C,
cooled to room temperature and left at 48C for 48 h
prior to use in competition dialysis. All nucleic acid solu-
tions were extensively dialyzed against Na2HPO4 (6mM),
NaH2PO4 (2mM), NaCl (185mM), EDTA (0.1mM), pH
7 using Pierce (Rockford, IL, USA) 3500 Da molecu-
lar weight cutoﬀ dialysis cassettes. All nucleic acid struc-
tures were characterized by circular dichroism spectra,
UV absorbance spectra and thermal denaturation, as
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previously described (26). All nucleic acid samples were of
identical concentration of 75 mM, expressed in terms of
monomeric unit (base pairs for duplex DNA, triplets for
triplex DNA and tetrads for quadruplex DNA). The
monomer concentration scale was used to alleviate possi-
ble problems arising from length diﬀerences among the
polynucleotide and natural DNA samples. At the end of
the dialysis equilibration period, ligand concentrations
were determined by ﬂuorescence. A volume of 180 ml of
each sample was carefully transferred into one well of a
96-well microtiter plate (Costar cat 3915; Corning Inc.,
Corning, NY, USA). To each sample, 20 ml of a 10% (w/v)
sodium dodecyl sulfate (SDS) stock solution was added to
give a ﬁnal concentration of 1% (w/v) SDS. The technique
of adding SDS has been used extensively by many research
groups for dissociating ligands from nucleic acid struc-
tures (46). Dissociation of the ligand from the DNA is
critical to ensure that there are no complexities arising
from diﬀerences in the optical properties of free and
bound ligands. The total ligand concentration (Ct)
within each dialysis well was determined using a ﬂuores-
cence standard curve for each tested ligand. Appropriate
corrections were made for the small dilution resulting
from the addition of the SDS stock solution. The
free ligand concentration (Cf) was determined from an
aliquot of the dialysate solution, which typically did not
vary signiﬁcantly from the initial 1 mM concentration.
Fluorescence measurements were made using a Saﬁre
microplate reader (Tecan US, Durham, NC, USA), with
the following parameters: excitation and emission band-
width, 10 nm, gain: 100. Compound OZ-85H: exc./
emission 260/494 nm, compound MHQ-15: exc./emission
260/437 nm, compound 1 exc./emission 260/490 nm, com-
pound 2: exc./emission 348/446 nm. The bound ligand
concentration (Cb) was then determined by:
Cb ¼ Ct  Cf 1
Binding constants, speciﬁcity sums (SS) and the ratio
Cb/SS were calculated as previously described (46) and
are provided in Supplementary Equation (S1).
CD titration and thermal denaturation methods
CD titrations were done as previously described (47),
using a Jasco 810 spectropolarimeter. Instrument settings
were: wavelength range (220–500 nm), scan rate (100 nm
min1), averaging time (0.125 s), bandwidth (1 nm),
number of scans (2), temperature (208C). The eﬀect of
ligands on the thermal denaturation of triplex DNA was
studied using the exact protocol described previously (46).
RESULTS AND DISCUSSION
Virtual screening
The initial step in virtual screening was performing
Surﬂex-Sim to determine which of the ligands in the
library were most structurally similar to the known, triplex
selective intercalator MHQ-12. Of the approximately 2
million ligands screened for similarity against MHQ-12,
350 ligands had a Surﬂex-Sim score of greater than 0.70
(range 0.875–0.704) and were selected for Surﬂex-Docking
studies. A cutoﬀ Surﬂex-Sim score of 0.70 was selected
based on previous studies which suggested that this is
the lowest score where the ligand structure–function rela-
tionship is typically maintained (25). The next step in
the virtual screening process involved performing
Surﬂex-Dock studies with the top 350 ranked Surﬂex-
Sim ligands using the intercalation site and the three
grooves (major–major, major–minor and minor) of the
triplex as individual docking targets. Interestingly,
MHQ-12 has the top Surﬂex Raw Score out of all 350
ligands that were docked to the intercalation site, which
directly supports the ability of Surﬂex-Dock to success-
fully dock and rank a known selective triplex intercalator.
We propose a new metric to evaluate the Surﬂex-Dock
results, the ‘Normalized Surﬂex Raw Score (NSRS)’.
The rationale behind the normalization of the Surﬂex
Raw Score is that the score for a ligand binding to a
single site on a target measures only the interaction with
that one site. However, a ligand may have multiple inter-
action sites on a particular target. Therefore, for selectivity
for a particular mode of binding, it is crucial to determine
the binding of the ligand to the site of interest relative to
the binding to other potential sites on the target. Since
ligands interact with nucleic acids typically through
either the groove-binding or intercalation, protomols
were constructed at the three grooves and the intercalation
site (48). Binding of the ligand to the intercalation site
relative to binding in the three grooves embodies the ‘nor-
malized’ aﬃnity and speciﬁcity of the ligand for triplex
intercalation. The following metric determines the NSRS
for the intercalation site for each of the top 350 Surﬂex-
Dock results:
NSRSintercalation site
¼ SRSintercalation site
Maximum SRSmajormajor site, majorminor site, minor site
2
Ranking of the 350 intercalation site Surﬂex-Dock results
by NSRS shows that only three ligands have a higher
NSRS score than MHQ-12 (NSRS of 6.8) (Figure 1A).
The ligands are LS-08 (49) (Figure 1B), compounds 1
(Figure 1E) and 2 (Figure 1F) and have NSRS values of
7.03, 7.34 and 7.39, respectively (Figure 1). Interestingly,
LS-08 (Figure 1B) which was identiﬁed by our virtual
screening methodology, was previously tested by Chaires
(46) and shown to be highly triplex selective, which adds
validity to our virtual screening approach used to identify
triplex selective ligands. Based on the NSRS values, com-
pounds 1 (Figure 1E) and 2 (Figure 1F) were hypothesized
to have superior aﬃnity and selectivity for binding to the
triplex nucleic acid, and were tested by competition dialy-
sis. Two known triplex selective compounds, MHQ-15
(Figure 1C) and OZ-85H (Figure 1D) served as positive
controls, as these compounds have been extensively stud-
ied and characterized (18). Biophysical characterization
was performed by circular dichroism and thermal dena-
turation to assess the ability of the compounds to interca-
late into the DNA triplex.
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Competition dialysis
The results of the competition dialysis experiments are
shown in Figure 2. It is visually apparent that compounds
1 and 2 have a much higher aﬃnity for the TAT triplex
than the two positive control reference compounds,
MHQ-15 and OZ-85H. The competition dialysis results
for MHQ-12 have previously been described in detail
(18), and this compound has an SS of 1.32 and a Cmax/
SS ratio of 8.93. Determination of the SS (Table 1) for
compounds 1 and 2 demonstrates superior triplex selectiv-
ity compared to OZ-85H but slightly less selectivity than
MHQ-12 and MHQ-15. However, the signiﬁcantly higher
binding aﬃnities of compounds 1 and 2 translate to much
higher Cmax/SS values than MHQ-12, MHQ-15 or OZ-
85H. The Cmax/SS ratio for compounds 1 and 2 is signif-
icant as it suggests that compounds 1 and 2 have a supe-
rior combination of binding aﬃnity and selectivity
compared to the reference compounds. These results val-
idate the virtual screening approach, and show that the
method can be used to identify compounds with high
aﬃnity and selectivity for a target nucleic acid, in this
case the DNA TAT triplex.
Circular dichroism
The interaction of compounds 1 and 2 with DNA was
studied by circular dichroism (Figure 3). Both compounds
show pronounced induced circular dichroism (ICD) in the
Figure 1. Chemical structures of the ligands used in virtual screening
and competition dialysis experiments. (A) MHQ-12, (B) LS-08,
(C) MHQ-15, (D) OZ-85H, (E) compound 1 and (F) compound 2.
Figure 2. Competition dialysis results for MHQ-15, OZ-85H, com-
pounds 1 and 2. The concentration of bound ligand to each nucleic
acid structure in the array is shown.
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presence of triplex DNA. The ICD is in a spectral range
where the compounds absorb light but the DNA does not.
This ICD is unambiguous proof of the ligand binding to
triplex DNA. For both compounds 1 and 2, the ICD is
negative in sign, and relatively weak in magnitude. Such
behavior is consistent with an intercalative binding mode,
although the mode of binding can only be deﬁnitively
established by high-resolution experimental structural
analysis (50).
Thermal denaturation studies
Figure 4 shows the eﬀects of compounds 1 and 2 on the
thermal denaturation of the TAT triplex. In the absence of
added ligand, two transitions are seen, corresponding to
the melting of the third strand (308C) and the duplex
(708C). Titration with both ligands results in a clear ele-
vation of the ﬁrst transition, indicating stabilization of the
triplex. The eﬀect is maximal at saturating concentrations
of ligand (1:1, ligand:triplet), where melting of the triplex
coalesces with duplex melting. Melting of the triplex
is stabilized by 408C indicating tight binding of both
compounds. Neither compound 1 nor compound 2 alters
the transition temperature of the duplex form to any
appreciable extent, an observation that is fully consistent
with the weak binding to duplex seen in competition dia-
lysis experiments (Figure 2).
Validation of QSAR
In the previous study of naphthylquinoline binding to tri-
plex DNA (18), a QSAR was derived from competition
Figure 3. Induced circular dichroism results for (A) compound 1 and
(B) compound 2. (A) Spectra are shown for a ligand concentration of
45 mM in the presence of triplex DNA ranging from 5 mM to 450mM
triplets. (B) Spectra are shown for a ligand concentration of 22.5mM in
the presence of triplex DNA ranging from 2.25 mM to 225mM triplets.
Figure 4. Thermal melting results for (A) compound 1 and (B) com-
pound 2. Derivative melting curves were obtained using 32 mM triplex
DNA and ligand concentrations ranging from 0 to 16 mM (A) or 0 to
32 mM (B). The peak near 308C is for the melting of the third stand,
while that near 708C is for melting of the duplex.
Table 1. Competition dialysis metric results for the positive controls,
MHQ-15, OZ-85H and the virtual screening top results, compounds
1 and 2
Test ligand Cb (mM) Kapp/10
5 (M1) SS Cmax/SS (mM)
MHQ-12a 11.8 1.87 1.32 8.93
MHQ-15 10.7 1.7 1.66 6.44
OZ-85H 17.6 3.1 3.69 4.77
Compound 1 24.2 4.8 2.30 10.47
Compound 2 30.0 6.7 1.92 15.63
aThese data are included from a previous publication (18).
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dialysis binding data. The best three-term QSAR to
emerge was:
logKapp ¼ 0:00264ð0:00065ÞSASA 0:693ð0:125ÞEA
 0:196ð0:02ÞHBa þ 4:66ð0:44Þ
N ¼ 14;R ¼ 0:959;RMSE ¼ 0:130;
F ¼ 49:84;P ¼ 0:0001 3
In this relationship, log Kapp is the logarithm of the appar-
ent binding constant (Table 1), SASA is the total solvent
accessible surface area in A˚2, EA is electron aﬃnity in eV
and HBa is the number of hydrogen bond acceptors. The
physical meaning of this is as follows. As SASA increases,
log Kapp increases in magnitude, indicating higher aﬃnity
for triplex DNA. Increases in the magnitudes of EA and
HBa result in decreasing binding aﬃnity. Increasing the
solvent-accessible surface areas of naphthylquinoline com-
pounds results in higher aﬃnity for the triplex. Greater
electron aﬃnity and more hydrogen bond acceptors
reduce the aﬃnity of naphthylquinolines for triplex DNA.
Binding data obtained for compounds 1 and 2 in this
study validate the published QSAR. The molecular
descriptors SASA, EA and HBa were calculated using
QikProp, and substituted into Equation (3). For com-
pound 1, log Ka=5.07 was predicted, compared to a
measured value of log Kobs=5.68. For compound 2,
log K-values of 5.18 and 5.82 were calculated and
observed, respectively. The diﬀerences in calculated and
observed values correspond to a factor of about four in
binding constants, an acceptable agreement for predic-
tions from a QSAR.
Triplex-binding ligands
While these newly reported compounds have some of the
tightest binding properties found to date by competition
dialysis, it is worth considering limitations to this plat-
form. One consideration is that the array of nucleic
acids used in the assay is not all-encompassing and repre-
sents only a broad number of structural and sequence
variants. Certain morphologies of nucleic acids to which
ligands may bind may not be present in the array.
To address this, current eﬀorts are underway to expand
the assay to include a larger number of nucleic acid solu-
tions. This limitation also highlights however that a key
beneﬁt of competition dialysis is the ability to customize
any number of targets for the assay. As new potentially
therapeutic nucleic acid structures are discovered, they can
be added to the assay and screened using this platform.
Another consideration from these results is that the assay
remains particularly relevant as an in vitro test, but may
not necessarily reﬂect in vivo conditions and ligand bind-
ing behavior. This is particularly true when considering
diﬀerences in the abundance of various forms of nucleic
acids. For example, because of the abundance of duplex
DNA, the observed approximately 5-fold diﬀerence in
binding of compound 2 to the TAT triplex may be insuf-
ﬁcient to overcome non-speciﬁc binding of the ligand to
duplex DNA in vivo. However, this may be irrelevant if
ligands are discovered that bind with true selectivity
and high aﬃnity to only a single nucleic acid structure.
While these are some relevant considerations when
using this platform, the approach as demonstrated here
is valuable for identifying potential small molecules with
desirable binding properties for a single nucleic acid
structure.
CONCLUSION
This work demonstrates a novel strategy for discovering
small molecules that can selectively bind to the triplex
nucleic acid, poly(dA)-[poly(dT)]2. Through the combina-
tion of virtual screening by Surﬂex and experimental val-
idation by competition dialysis, compounds 1 and 2 were
discovered. These compounds have the highest overall
aﬃnities and selectivities reported for triplex binders as
determined by competition dialysis. Further biophysical
characterization by circular dichroism and thermal melt-
ing conﬁrmed the mechanism of action of these new com-
pounds and veriﬁed the predictive nature of the virtual
screening methodologies. Several aspects of the virtual
screening results are noteworthy. First, the combination
of a ligand-based (Surﬂex-Sim) with a structure-based
approach (Surﬂex-Dock) proved to be a powerful and
highly computationally eﬃcient way to identify triplex
selective small molecules, as Surﬂex-Sim is two orders of
magnitude faster than Surﬂex-Dock. Second, our develop-
ment of the NSRS metric, which can predict a particular
mode of binding of triplex selective ligands with both sim-
ilar and diﬀerent (scaﬀold hopping) chemical scaﬀolds.
This is signiﬁcant as it has the potential to identify new
classes of small molecules that may have much higher
aﬃnity and selectivity for a given nucleic acid target.
Future work will focus on extending this integrated virtual
and actual screening platform to target other nucleic acid
structures that may hold medicinal value and physiologi-
cal relevance.
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